drugset / Trial / NCT05216354
Fruquintinib Renal Impairment Study
Non-randomizedSequentialOpen-labelOther
Summary
A multicenter, open label, single-dose, single-period, sequential study to assess the effect of renal impairment on the pharmacokinetics of Fruquintinib
Timeline
- Start
- 2022-03-11
- Primary completion
- 2023-06-26
- Completion
- 2023-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 2 mg | — |
| Subject | Fruquintinib | Small molecule | 5 mg | — |